🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Staples Sector SEC Filings — May 04, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, personal care with adjacent industrials/energy), overarching themes include mixed Q1 2026 earnings with revenue growth averaging +8% YoY in reporting firms (e.g., Krystal +32%, Powell +6%) but frequent profit declines (-20% avg in mixed reporters like Exxon -46%, NCL EPS double but FY guidance cut) due to cost pressures, margin compression (~150 bps avg in 7/15 metrics), and working capital strains. M&A activity surges with accretive deals like GNL-Modiv ($535M, +4% AFFO, Q3 close) and Hubbell-NSI ($3B, +EPS 2026), signaling consolidation; capital returns robust via buybacks ($66M New Mountain, $548M Diamondback) and dividends (Great Elm 18% yield, SmartStop $1.60 ann.). Portfolio-level patterns show 6/10 mixed sentiment filings with NAV declines (e.g., New Mountain -5.2%, Great Elm -4%) amid unrealized losses, but positive catalysts in FDA approvals (ADMA) and order backlogs (Powell +33% to $1.8B). Implications: Favor M&A beneficiaries and capex raisers (Diamondback oil +5% FY guide) over guidance cutters (NCL yields -3-5%); sector faces margin headwinds but strong liquidity supports returns.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 04, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors), overarching themes include mixed Q1 2026 earnings with 6/10 reporting companies showing revenue growth averaging +20% YoY (e.g., Biodesix +42%, Backblaze +11.7%) offset by declines in cyclicals like Boise Cascade (-2% sales YoY) and Cogent (-3.2% YoY), alongside accretive M&A in industrial real estate and positive capital raises/licensing in health-adjacent industrials. EBITDA margins expanded in 7/12 key filers (avg +200bps YoY, driven by cost controls at Boise +136% BMD EBITDA growth and Backblaze +800bps to 26%), signaling operational resilience amid softening demand from housing starts (-5% YoY). Capital allocation remains shareholder-friendly with $65.5M Boise buybacks, $548M Diamondback repurchases, and consistent dividends (e.g., Marzetti $0.12/share). Forward-looking catalysts cluster in Q2-Q3 2026, including merger closes, guidance realizations, and clinical data readouts. Institutional 13F snapshots (16/50 filings) reveal heavy tech/industrials tilts (e.g., Vertiv, BWX Tech), indicating conviction in infrastructure/AI themes. Most critical: Global Net Lease's $535M industrial acquisition (4% AFFO accretive, Q3 close) and Biodesix's 42% revenue surge with raised FY guidance, positioning select industrials for outperformance vs. sector peers.

16 high priority 34 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 04, 2026

Across 50 SEC filings from May 4, 2026, dominant themes include a surge in M&A activity (e.g., GNL's $535M acquisition of MDV, Lattice's $1.65B AMI deal, Ecovyst's INEOS purchase) and SPAC developments (e.g., Collective II $220M IPO, Blueport $1.2B SingAuto deal, Flag Ship termination), signaling robust dealmaking in industrials, tech, and SPACs despite one notable bankruptcy at SG Echo. Period-over-period trends show revenue growth in key reporters: Lattice +42.2% YoY, Ameresco +14% YoY, Sonos +8% YoY, GECC NII +13% QoQ, but mixed with NAV drops (GECC -4.1% QoQ, New Mountain -5.2% QoQ) and margin pressures (Ameresco gross margin 14% impacted by weather). Leadership changes abound (26/50 filings), mostly orderly transitions (e.g., Publix, Aura Biosciences, Hercules Capital) with positive sentiment, alongside biotech financings (Cabaletta $150M, Rein $50M) bolstering cash for trials. Capital allocation leans shareholder-friendly: GECC $0.25 dividend (18% yield), Intuitive $5B buyback increase, Track Group debt cut 63%. Forward-looking catalysts cluster in Q3 2026 (multiple closings) with biotech trial data into 2027. Portfolio-level: Industrials/REITs M&A accretive (GNL +4% AFFO), biotech optimistic on offerings/trials, but watch mixed financials and SPAC risks for volatility.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 04, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (May 4, 2026 period), dominant themes include aggressive M&A in industrial/REIT space (GNL-Modiv $535M all-stock deal, 4% AFFO accretive, 17% premium), mixed Q1 2026 earnings with pharma/biotech revenue growth averaging +7-8% YoY (Evolus +7%, Vertex +8%) offset by declines in offshore drilling (-13% QoQ Valaris) and telecom (-3.2% YoY Cogent), and robust capital allocation via buybacks/repurchases (Indivior $175M ASR, Progressive $467M treasury shares). Institutional 13Fs (14 filings) reveal heavy tech concentration (e.g., NVIDIA, Amazon top holdings across Yahav, Triglav, Montaka), signaling sustained bull market conviction. Forward-looking data flags lowered guidance (Norwegian Cruise Net Yield -3-5%, EPS $1.45-1.79) amid demand softness, contrasted by reaffirmed targets (Evolus $327-337M revenue). Bankruptcies (Safe & Green, Spirit Aviation wind-down) highlight distress in niche industrials/aviation. Portfolio-level trends: 6/12 earnings filings show YoY revenue growth >5% but 4/12 with EBITDA/affo declines; capital returns strong in 5 firms (dividends, buybacks up YoY). Actionable: M&A catalysts in Q3 2026, watch biotech data readouts H1-H2.

14 high priority 36 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 04, 2026

The May 4, 2026, SEC filings reveal a surge in IPO amendments (e.g., Cerebras, GMR Solutions, Odyssey Therapeutics, Liftoff Mobile, Fervo Energy) across AI, biotech, and EMS sectors, signaling robust capital market access amid high valuations ($115-125/share for Cerebras). M&A activity dominates industrials/REITs with Global Net Lease's $535M acquisition of Modiv Industrial (17% premium, 4% AFFO accretive, Q3 close), alongside SPAC deals like Blueport-SingAuto ($1.2B). Q1 2026 earnings show mixed results: revenue growth averaging +7% YoY (e.g., Berkshire +4.4%, NCLH +10%, Illumina +4.8%) but margin pressures in insurance (CNA combined ratio +380bps to 102.2%, Loews CNA down 23%) and widening biotech losses (Odyssey +15% YoY to $148.6M). 13F filings highlight persistent tech concentration (NVIDIA, MSFT, AAPL top holdings across filers like AMF, Triglav). Forward guidance includes cuts (NCLH FY Net Yield -3-5%) and positives (Cabaletta H1/H2 2026 data), with capital allocation favoring dividends (CNA $0.48) and debt reduction (Cushman partial redemption). Portfolio-level trends: 8/15 earnings filers grew revenues YoY but 6/8 showed NI declines; biotech sentiment mixed due to R&D ramps.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 04, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with cross-sector exposure via REITs, food/retail, and industrials), sentiment is predominantly mixed (14/50), reflecting revenue growth averaging +12% YoY in 18 earnings reporters (e.g., Sterling +92%, L.B. Foster +24%, Tyson +4.4%) but offset by profitability challenges like impairments (Armada net loss worsened to $33.3M) and volume declines (FreightCar -33%, OneWater -8.5%). Guidance trends are resilient with 6 raises/reaffirmations (Armada FFO to $0.51-$0.55, Sterling EBITDA to $843-873M), signaling management conviction amid restructuring (e.g., Armada $562M portfolio sale, $700M debt paydown). Capital allocation favors shareholders via $24.1M buybacks (Armada), dividends (Tyson $0.48, Superior $0.14, SmartStop $1.60 annualized), and M&A approvals (Farmer Bros 86.9% yes). IPO activity (GMR, Liftoff, Fervo) and SPAC developments (Willow neutral, Flag Ship terminated) highlight deal flow risks/opportunities. Institutional 13Fs (11 filings) show stable heavy weighting in consumer/tech names like Costco, Amazon (e.g., Garrison top Costco $10M). Portfolio-level: Margin expansion in winners (Marzetti + to 23.6%) vs compression elsewhere; actionable now on raised guidance and near-term catalysts like May 15 Cushman redemption.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 04, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader financial crossovers), mixed sentiment dominates healthcare/biotech names, with 4/7 key players (Twist, Vertex, Merck, Aura) showing YoY revenue growth averaging +12.8% (Twist +19%, Vertex +8%, Merck +4.9%) but widening net losses due to elevated R&D/SG&A (e.g., Twist net loss +12% YoY to $44M, Merck $4.2B loss from $8.5B acquisition charge), signaling heavy investment in pipelines amid 99% revenue plunge outlier at Akston Biosciences IPO. Capital allocation leans bullish with buybacks surging (Intuitive Surgical $5B authorization, Tidewater $500M, New Mountain $66M YTD +$50M more, Aura $39M repurchase), dividends steady (CNA $0.48, Corebridge $0.25), and share repurchases reflecting management conviction despite NAV declines (New Mountain -5.2% to $10.92). Leadership transitions positive in healthcare (Aura new CEO Natalie Holles, Edwards new CFO Doretta Mistras), while non-healthcare finance/insurance shows stable NII but margin pressures (CNA combined ratio +380bps to 102.2%, Loews net income -9%). Forward guidance largely raised/reiterated (Twist FY26 rev to $442-447M +17-19% growth, Vertex $12.95-13.1B), building H2 2026-2027 catalysts like Aura Phase 3 topline. 13F filings (9 total) reveal neutral institutional positioning with heavy ETF/tech tilts but healthcare exposure (e.g., Thermo Fisher, UnitedHealth). Portfolio-level: Healthcare growth intact but loss-making (avg gross margin +100bps at Twist), buybacks signal undervaluation, watch M&A (Corebridge-Equitable, Rallybio termination fee $50M). Actionable: Favor buyback-heavy medtech/biotech over plunging revenue IPOs.

17 high priority 33 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 04, 2026

Across these 10 DEF 14A proxy statements for US companies, a dominant theme is preparation for mid-June 2026 annual meetings, with 9/10 virtual and focused on routine governance items like director elections (all 10), say-on-pay advisory votes (8/10), and auditor ratifications (10/10), signaling stable board continuity amid executive compensation scrutiny. Financial highlights are sparse but reveal stark contrasts: National Vision Holdings stands out with FY2025 revenue +9.0% YoY to $1,987.5M, Adjusted Op Income +56.5% YoY to $102.5M (margin +5.2pp to 8.8%), and Adj EPS +53.8% YoY to $0.80, while STAAR Surgical reports a challenging FY2025 with slower growth and merger rejection but positive 2026 momentum from EVO+ exceeding expectations in China. Veeva Systems signals strong shareholder alignment via $2B buyback and engagement with 40% of shares, contrasting dilution risks in Wellgistics (blank check preferred) and Xos (plan expansion + note conversions >20% shares). Mixed/neutral sentiments prevail (7 neutral, 2 positive, 2 mixed), with no widespread insider trading or capital allocation shifts beyond Veeva's repurchase; portfolio-level trends show healthcare/tech firms prioritizing equity incentives amid governance enhancements like Helios' clawback policy. Market implications include low volatility from routine votes but alpha from outliers like National Vision's growth and STAAR's turnaround, with clustered catalysts in June 2026.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 04, 2026

The IPO Pipeline stream features three S-1 filings dated May 4, 2026, dominated by dilutive resale registrations for Acurx Pharmaceuticals (two filings totaling ~2.95M shares) and a high-materiality SPAC IPO by Keystone Acquisition Corp ($250M base, up to $287.5M). No period-over-period financial trends (YoY/QoQ revenue/margins) are detailed, but pricing data reveals Acurx shares issued at low weighted average $3.07 post-Dec 2025 vs higher warrants ($7.25/$2.78), signaling share price pressure and funding desperation in biotech. Keystone's standard SPAC structure with founder shares at $0.003 highlights classic low-cost promotion potential. Overarching themes include biotech reliance on equity lines/warrants for working capital amid dilution risks (mixed/neutral sentiment), contrasted by resurgent SPAC activity. Critical implications: Acurx faces liquidity/price declines, while Keystone IPO could catalyze M&A hunting; portfolio-level pattern shows 2/3 filings as non-traditional 'IPOs' via resales, underscoring weak primary capital raise momentum.

3 high priority 3 total filings
· daily

US Earnings Financial Results SEC Filings — May 04, 2026

Across 50 Q1 2026 US SEC filings, revenue growth was resilient with 38/50 companies reporting YoY increases averaging 12.5% (range 0.7%-2600%), driven by core operations, acquisitions, and international expansion, though profitability was volatile with 25 firms seeing net income declines due to impairments, higher costs, and one-offs. Margin trends mixed: gross margins expanded in 22 cases (avg +500bps in food/tech) but compressed in energy/insurance (avg -200bps). Capital allocation robust with $15B+ in dividends/buybacks (e.g., Progressive $8B dividend, Berkshire $236M buybacks), signaling management confidence amid $20B+ M&A spend. Biotech/pharma (12 firms) narrowed losses 40% avg on rev ramps, energy/oil (5 firms) faced input cost pressures (-30% NI avg), financials (8 firms) grew NII 8% avg with stable provisions. No major guidance changes noted, but forward capex/dividend hikes flag H2 catalysts; mixed sentiment (46/50) implies sector rotation opportunities in improving biotechs vs pressured cyclicals. Portfolio implication: overweight growth biotechs/financials, underweight energy amid OPEX inflation.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 04, 2026

Both Hoth Therapeutics and Jaguar Health face severe Nasdaq delisting risks, with negative sentiment and high materiality (9-10/10), highlighting a pattern of compliance failures in the biotech sector on the Nasdaq Capital Market. Hoth received a bid price deficiency notice for 30 consecutive days below $1.00 (March 18-April 29, 2026), granting 180 days until October 27, 2026, to cure, while Jaguar, post a 1-for-35 reverse stock split on April 30, 2026, failed the 500,000 publicly held shares requirement (only 401,226 shares), adding to its bid price issues and triggering a May 8, 2026, response deadline to the Hearings Panel. No period-over-period financial trends, revenue growth, or margin data provided in filings, focusing purely on regulatory halts risks; no insider trading activity, capital allocation changes (beyond reverse split), or M&A noted. Cross-company comparison shows Jaguar's situation more acute (materiality 10/10 vs 9/10) due to recent reverse split failure, signaling portfolio-level distress in low-float biotechs. Market implications include potential trading suspensions, delistings, and heightened volatility, urging avoidance or short strategies for exposed positions.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 04, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, the dominant theme is proactive distress resolution through M&A (e.g., GNL-Modiv $535M all-stock deal, Assertio-Garda $153M tender), equity offerings (Cabaletta $150M, Rein $50M), and debt amendments/extensions (Track Group net debt -63% to 2.6x leverage, Alcoa maturity to 2028), offsetting outright distress like SG Echo Chapter 11 bankruptcy and Nasdaq delisting risks (Hoth, Jaguar). Period-over-period trends show resilient revenue growth in select names (Ameresco +14% YoY Q1 2026, Lattice +42% YoY Q1 revenue to $170.9M) but mixed profitability (Ameresco net loss widened to $18.3M YoY, Lattice op cash flow margin -10.1pp QoQ). Capital allocation leans toward deleveraging and shareholder alignment (Track Group PIPE + new board owning 75%, Turtle Beach $49M buybacks), with forward-looking catalysts clustered in Q2-Q3 2026 (multiple M&A closings, Modiv vote). Portfolio-level patterns reveal biotech/pharma heavy (10+ filings) pursuing financings amid dilution risks, industrials consolidating via acquisitions, and sparse insider sales but new director additions signaling conviction. Overall, signals point to turnaround opportunities outweighing pure bankruptcies, with 7/43 filings showing margin stability or gains (Lattice +100bps YoY gross margin). Market implication: Distressed assets trading at premiums in M&A (Modiv 17-28%, Garda 63% to unaffected), favoring event-driven strategies.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — May 04, 2026

Across 45 filings in the USA Executive & Director Changes stream (33 new), a wave of 20+ CEO/CFO/executive transitions dominates, including 8 retirements/planned departures (e.g., Publix Executive Chairman, Occidental CEO, Exxon CAO, Pool Corp CEO, Adeia CEO) and 15+ appointments/promotions (e.g., Aura CEO, Hercules President/CFO, Edwards Lifesciences CFO from Viatris), signaling proactive leadership refreshes amid sector pressures. Financial trends where reported show mixed results: BDCs like New Mountain (NII flat YoY at $0.32/share, NAV -5% QoQ to $10.92) and Great Elm (NII +13% QoQ to $0.36/share but NAV -4% QoQ to $7.74) highlight portfolio volatility; Sonos Q2 rev +8% YoY to $282M with first positive EBITDA in 4 years; Pinterest Q1 rev +18% YoY to $1.008B but net loss widened to $74M. Capital allocation remains shareholder-friendly with repurchases (New Mountain $66M YTD +$50M auth, Great Elm 1% shares at 36% NAV discount, Intuitive $5B program increase) and dividends (Great Elm $0.25/share Q2, 18% yield). Positive sentiments in 60% of filings (e.g., hires with deep expertise), but mixed/neutral in departures; biotech hires (Aura, Pasithea, Tivic) tie to trial catalysts. Portfolio-level: Margin stability in consumer/tech offset by BDC NAV erosion; energy/retail transitions orderly. Implications: Opportunities in growth-oriented hires (biotech, semis), risks in BDC volatility and sudden CFO churn (5 cases).

45 high priority 45 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 04, 2026

Across 45 filings on USA Board Room Changes from May 4, 2026, a dominant theme is C-suite and board transitions, with 18 CEO/President/CFO changes (9 appointments, 9 departures/retirements), 12 new director additions, and 8 annual meetings showing strong shareholder approval (avg 95%+ for directors/say-on-pay). Period-over-period trends reveal mixed financial health: revenue growth in 4/7 reporters (Sonos +8% YoY Q2, Pinterest +18% YoY Q1 avg ARPU +6%, GECC NII +13% QoQ Q1, New Mountain NII flat YoY), but NAV declines in BDCs (GECC -4% QoQ to $7.74, New Mountain -5% to $10.92) and losses (Sonos Q2 GAAP net loss $29M improved YoY, Pinterest Q1 loss widened to $74M). Capital allocation remains shareholder-friendly with $5B Intuitive Surgical buyback increase, $2B Pinterest repurchases, GECC $57.5M note calls/$0.5M share buyback, New Mountain $66M YTD repurchases +$50M auth. Positive biotech appointments (Aura, Tivic, Pasithea) bolster trials, while planned energy transitions (Occidental, Exxon, Publix) signal continuity. Implications: Opportunities in experienced leadership hires amid churn, risks from interim roles and NAV pressure in BDCs/fintech.

45 high priority 45 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 05, 2026

Overnight SEC filings for May 5, 2026 reveal a mixed Q1 2026 earnings landscape across 50 companies, with 12/20 major reporters showing revenue growth averaging +15% YoY (e.g., Ecovyst +50%, Terex +41% reported), but 8 experiencing declines averaging -5% (e.g., Ingredion -1%, Gartner -1.5%), amid margin expansions in 7 cases (+ avg 150bps, DuPont to 24.6%) offset by compressions in 6 (- avg 200bps, Atkore to 18.6%). Guidance raises in 6 firms (DuPont FY sales $7.15-7.22B, ADM EPS $4.15-4.70, Ecovyst EBITDA $180-195M) signal confidence, while capital allocation favors buybacks ($535M Gartner, $275M DuPont ASR imminent) and dividends across 8 names. M&A/divestitures dominate (DuPont Aramids $1.2B sale, Expro $215M acquisition Q3 close, Coterra/Devon merger May 7 close), with SPAC IPOs (CH4 $200M, ARC $105M) adding liquidity. Energy sector shines with production up (Black Stone +16% QoQ), merger approvals; industrials mixed on costs/tariffs. Portfolio implication: overweight raised-guidance industrials/chemicals, monitor energy M&A catalysts for pre-market pops.

16 high priority 34 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 04, 2026

The May 04, 2026 FDA approval period in biotech small-cap stream delivered 10 'Other' approvals (0 NMEs, 0 biosimilars, 0 label expansions per mix), dominated by 9 biosimilar approvals and 1 NME, yielding 1 bullish and 9 neutral signals. No dominant therapeutic area theme emerged, though CNS/neurology saw clustering with biosimilars to OXCARBAZEPINE, VILOXAZINE HYDROCHLORIDE, CENOBAMATE, FLUVOXAMINE MALEATE, and DOXEPIN HYDROCHLORIDE. Highest-conviction signal is INSULIN GLARGINE-ALDY (LANGLARA) NME by SUNSHINE LAKE PHARMA CO LTD, signaling 5-year NCE exclusivity and diabetes market entry potential with high strength (8/10 materiality). Biosimilar entrants like APOTEX INC (SITAGLIPTIN) and AUROBINDO PHARMA LIMITED (CENOBAMATE) gain upside, balanced by bearish erosion risks for undisclosed originators (30-60% revenue potential over 2-3 years). Key risk/watch item: competitive dynamics from biosimilar launches pressuring neurology originator pricing power.

10 total filings
· daily

Orphan Drug Approvals — May 04, 2026

The FDA approved 1 Other drug in the Orphan stream (0 NMEs, 0 biosimilars, 0 label expansions) from May 04, 2026 to May 04, 2026, consisting solely of a label expansion for SELINEXOR by KARYOPHARM THERAPS. This bullish signal (strength 5/10, materiality 5/10) is the highest-conviction event, indicating positive execution for Karyopharm in the orphan space with potential to broaden SELINEXOR (XPOVIO)'s addressable market, though peak sales, exclusivity, pricing, and market position remain NOT_DISCLOSED. No dominant therapeutic area theme is present given the single approval. A key risk/watch item is Karyopharm's post-approval commercialization execution, as near-term catalysts are listed as N/A.

1 total filings
· daily

Contract Option Exercises — May 04, 2026

NASA Goddard Space Flight Center exercised options totaling $351,035,113 in obligations on a cost-plus-fixed-fee contract with ALCYON TECHNICAL SERVICES (ATS) JV, LLC, an SBA Certified 8(a) Joint Venture, for systems engineering services (NAICS 541712, PSC R425). This represents a 100% civilian agency award with 0 defense-related contracts, underscoring steady NASA spending in space systems R&D amid a neutral signal (avg strength 3.0/10). The dominant theme is sustained support for mission and instrument engineering at Goddard, performed in Greenbelt, MD, with $246,907,027 already outlayed and $7,385,356,524 in subawards across 2690 transactions. Highest-conviction signal is neutral continuation of this 8(a) competed set-aside from 2015 through 2023-11-30, implying low disruption risk but limited growth alpha. Key watch item: monitor outlay progress toward full $351M obligation and subawards execution, given the contract's end date has passed relative to the 2026 exercise period.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 04, 2026

Across 28 filings in the USA S&P 500 Technology stream (broadly including adjacent sectors like comms, medtech, and SPACs), Q1 2026 results show mixed trends: revenue declines in Cogent Communications (-3.2% YoY to $239M) and off-net (-17% YoY), offset by EBITDA margin expansion (+2.1% YoY to 29.3%) and wavelength surge (+90.8% YoY); Apple Hospitality REIT RevPAR +2.2% YoY but net income -11.3% YoY. Strong AGM outcomes at Intuitive Surgical (10/10 proposals passed, $5B buyback authorization) and Cogent (directors >90% FOR, CEO 1M RSU perf award) signal management alignment and conviction. SPAC activity peaks with AParadise merger approval but 19.6M share redemptions (93% of quorum), flagging dilution risks; Genco tender offer at $23.50/share adds M&A momentum. Capital allocation favors returns: Cogent $0.02/share dividend, Apple Hospitality $242.5M buyback remaining and forward hotel buys ($65.5M Q4'27, $143.7M Q2'28). 13F filings reveal fund conviction in tech-adjacent like TTM Technologies ($45.8M Emerald), NVIDIA/Apple (Paradiem), MSFT/AMZN (Camden). Portfolio-level: improving liquidity (Snow Lake cash +606% YoY) amid losses, neutral appointments (Block CAO, Ducommun director), setting up catalysts in tenders/AGMs.

15 high priority 13 medium 28 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 04, 2026

S&P 500 Energy sector filings reveal mixed Q1 2026 performance, with ExxonMobil (XOM) posting 2.4% YoY revenue growth to $85.1B but a sharp 45.8% YoY net income drop to $4.2B due to higher costs and Energy Products losses, contrasting Hess Midstream's (HESM) stable results with Adjusted EBITDA up 2.6% YoY to $299.8M. Major M&A advances with Devon Energy (DVN) and Coterra (CTRA) merger overwhelmingly approved (98-99% votes), set to close ~May 7, enhancing scale in E&P. Leadership transitions signal continuity: XOM elects new Chief Accounting Officer effective July 1, Occidental (OXY) names COO Richard Jackson as CEO from June 1. Capital returns remain robust, with XOM deploying $9.2B on buybacks/dividends, HESM repurchasing $60M units/shares and hiking distributions 2.4% to $0.7792/share. Williams Companies (WMB) shows strong governance via AGM approvals (91-99% support). Non-energy filings like 13Fs and SPACs add neutral context but no sector impact. Overall, cost pressures challenge integrateds/midstream, but M&A catalysts and returns support resilience.

8 high priority 5 medium 13 total filings